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Introduction {#path4633-sec-0001}
============

Background -- SCCOHT {#path4633-sec-0002}
--------------------

Small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) is a rare ovarian cancer that predominantly affects young women in their teens and 20s, with an average age of 24 years. Although half of tumours are diagnosed at an early stage, the prognosis is dismal. For patients with stage IA disease, more than half will still die of disease, usually within 2 years [1](#path4633-bib-0001){ref-type="ref"}. Histologically, SCCOHT is characterized by sheets and poorly formed nests of small cells with scant cytoplasm, hyperchromatic nuclei, and small nucleoli [1](#path4633-bib-0001){ref-type="ref"}. Approximately half of tumours also contain variable numbers of large cells with abundant eosinophilic cytoplasm, often rhabdoid inclusions, large nuclei, and prominent nucleoli. The histological differential diagnosis is broad and includes many primary and metastatic tumours to the ovary. The lack of familiarity of pathologists with this rare tumour and the lack of specific immunohistochemical markers can make its diagnosis challenging.

SMARCA4 in SCCOHT and cancer {#path4633-sec-0003}
----------------------------

Recently, four groups independently identified inactivating *SMARCA4* mutations in the majority of SCCOHTs, resulting in loss of SMARCA4 protein [2](#path4633-bib-0002){ref-type="ref"}, [3](#path4633-bib-0003){ref-type="ref"}, [4](#path4633-bib-0004){ref-type="ref"}, [5](#path4633-bib-0005){ref-type="ref"}. SMARCA4 and the related protein SMARCA2 (also called BRG1 and BRM, respectively) are the two mutually exclusive ATPases of the SWI/SNF chromatin remodelling complex [6](#path4633-bib-0006){ref-type="ref"}, [7](#path4633-bib-0007){ref-type="ref"}, [8](#path4633-bib-0008){ref-type="ref"}. SWI/SNF subunits have been frequently implicated as tumour suppressors, with approximately 20% of cancers bearing mutations in these genes [9](#path4633-bib-0009){ref-type="ref"}, [10](#path4633-bib-0010){ref-type="ref"}. Our initial analysis of a small collection of ovarian tumours indicated that SMARCA4 loss was highly specific for SCCOHT [2](#path4633-bib-0002){ref-type="ref"}.

Potential therapeutic strategies for SCCOHT {#path4633-sec-0004}
-------------------------------------------

The function of the SWI/SNF complex in chromatin remodelling suggests that the pathogenesis of SCCOHT involves epigenetic dysregulation. This paradigm may offer treatment possibilities with agents that regulate the epigenome such as inhibitors of histone deacetylase (HDAC) or modifiers of histone or DNA methylation. The mutually exclusive nature of the SMARCA4 and SMARCA2 ATPases in the SWI/SNF complex has suggested that SMARCA2 may be a synthetic lethal target in *SMARCA4*‐mutant cancers. Indeed, loss of SMARCA4 has been shown to lead to dependence on SMARCA2‐containing SWI/SNF complexes for survival in some cell lines [11](#path4633-bib-0011){ref-type="ref"}, [12](#path4633-bib-0012){ref-type="ref"}, [13](#path4633-bib-0013){ref-type="ref"}, raising the possibility of targeting SMARCA2 in SCCOHT using inhibitors of its ATPase or bromodomain.

Aims of this study {#path4633-sec-0005}
------------------

The establishment of *SMARCA4* mutation with accompanying loss of protein as the pathognomonic mutation in SCCOHT raises the need to explore the spectrum of tumours that share SMARCA4 (and perhaps SMARCA2) loss to understand the diagnostic utility of SMARCA4 immunohistochemistry (IHC). Because some ovarian and uterine tumours arise from common cell types (eg endometrial epithelium, either in the eutopic endometrium or ectopically as endometriosis), we also need to determine the diagnostic utility of SMARCA4 IHC in uterine tumours. Therefore, the goals of this study were (1) to determine the specificity of SMARCA4 protein loss as a diagnostic marker for SCCOHT by studying its expression in a large cohort of ovarian and uterine tumours with an emphasis on entities in the differential diagnosis; and (2) to determine whether SMARCA2 is expressed in SCCOHT and could be used as a therapeutic target.

Materials and methods {#path4633-sec-0006}
=====================

Sample collection and tissue microarray construction {#path4633-sec-0007}
----------------------------------------------------

Duplicate 0.6 or 1.0 mm cores of formalin‐fixed, paraffin‐embedded tumour tissue from each case were used for tissue microarray (TMA) construction, as described previously [14](#path4633-bib-0014){ref-type="ref"}. Additional cases were studied by whole‐slide IHC. All samples were collected in accordance with institutional guidelines and protocols. For Vancouver samples, informed patient consent was obtained under research ethics board (REB)‐approved protocols for all prospectively collected patient samples (REB H05‐60 199), archived samples (REB H02‐61 375), and for IHC analysis (REB H02‐61375).

Immunohistochemistry and scoring {#path4633-sec-0008}
--------------------------------

TMAs were cut at 4 µm thickness onto Superfrost + glass slides and were processed using the Ventana Discovery XT, and the Ventana Benchmark XT and Benchmark Ultra automated systems (Ventana Medical Systems, Tucson, AZ, USA). Immunohistochemical staining was performed with antibodies to SMARCA4 (1:25, clone EPNCIR111A, ab110641; Abcam, Toronto, Ontario, Canada), SMARCA2 (1:50, clone HPA029981; Sigma, St Louis, MO, USA), and SMARCB1/BAF47/INI1 (1:50, 25/BAF47, 612110; BD Biosciences, Mississauga, Ontario, Canada).

All TMAs were scored twice by a pathologist (ANK). For SMARCA4, tumours were scored as positive if any tumour cell nuclei showed staining; tumours scored as positive usually showed diffuse, moderate to strong staining. Tumours were scored as negative if tumour cell nuclei showed no staining only if adequate staining was detected in internal positive control cells (endothelium, lymphocytes or fibroblasts); absence of staining has previously been shown to correlate with the presence of inactivating mutations in *SMARCA4* [2](#path4633-bib-0002){ref-type="ref"}, [3](#path4633-bib-0003){ref-type="ref"}, [4](#path4633-bib-0004){ref-type="ref"}, [5](#path4633-bib-0005){ref-type="ref"}, [15](#path4633-bib-0015){ref-type="ref"}. No cytoplasmic SMARCA4 staining was observed. Since SMARCA2 absence was due to non‐mutational silencing, tumours were scored as positive for SMARCA2 if more than 5% of tumour cells showed nuclear staining. Tumours were scored as negative if tumour cells showed no nuclear staining, nuclear staining in up to 5% of cells, or only cytoplasmic staining. For both SMARCA4 and SMARCA2, tumours that showed no staining in tumour and stroma were considered technical failures and not scored. Each case on a TMA was represented as duplicate cores; one positive core was sufficient to count the case as positive.

Cell lines {#path4633-sec-0009}
----------

BIN67, SCCOHT1, and KGN cells were all grown in DMEM/F‐12 supplemented with 10% FBS. SVOG3e cells were cultured in 199/105 medium with 10% FBS. ES‐2 cells were cultured in RPMI supplemented with 10% FBS. All the cells were maintained in a humidified 5% CO~2~‐containing atmosphere at 37 °C and tested regularly for *Mycoplasma*.

Plasmids and lentivirus/retrovirus packaging {#path4633-sec-0010}
--------------------------------------------

The pLDpuro‐SMARCA4 and pLDpuro‐SMARCA2 plasmids were constructed by introducing the SMARCA4 and SMARCA2 from entry vectors (Genecopeia) into the pLDpuro‐EnVA destination vector (a gift of Dr Jason Moffat at the University of Toronto) using Gateway reactions (Life Technologies, Grand Island, NY, USA). To produce lentiviruses expressing SMARCA4 or SMARCA2, pLDpuro‐SMARCA4 or pLDpuro‐SMARCA2 was co‐transfected with packaging plasmids psPAX2 and pMD2.G into HEK293T cells. Supernatants were collected at 72 h for lentivirus preparation and infection.

Western blotting {#path4633-sec-0011}
----------------

Whole‐cell extracts were obtained for SDS‐PAGE electrophoresis using the SMARCA4 and SMARCA2 antibodies described above. Ponceau S staining or western blotting for vinculin (clone hVIN‐1, V9131; Sigma) was used to confirm equal protein loading.

Real‐time RT‐PCR {#path4633-sec-0012}
----------------

Total RNA was extracted from cells using RNeasy kits (Qiagen, Valencia, CA, USA) and quantitated by Nanodrop spectrophotometry. One microgram of total RNA was reverse‐transcribed into cDNA using random primers and Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA), followed by PCR amplification of SMARCA4 or SMARCA2 using the Power SYBR^®^ Green Master Mix (Life Technologies) according to the manufacturers\' instructions. GAPDH was used for normalization. The relative levels were calculated using the ΔΔCt method.

RNA isolation and gene expression microarrays {#path4633-sec-0013}
---------------------------------------------

Frozen tumour tissue was disrupted by sonication using the Covaris S‐2 system (Thermo Fisher Scientific, Waltham, MA, USA) and stabilized by addition of equal volumes of TRIzol (Life Technologies). BIN67 and SCCOHT1 cells were washed with PBS and lysed using TRIzol. Total RNA was purified using RNeasy micro kits (Qiagen). RNA from two premenopausal normal ovary donors (ages 32 and 37 years) was obtained from OriGene (Rockville, MD, USA), pooled (100 ng each), and used as a common reference. RNA integrity and purity were measured using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and a Nanodrop ND‐1000 Spectrophotometer. Labelled cRNA probes were prepared using Agilent\'s Low Input Quick Amp Labeling Kit and hybridized to Agilent Human Gene Expression 4 × 44 K microarrays following the manufacturer\'s protocols. Slides were washed and scanned at 5 µm using an Agilent Microarray Scanner (model G2505B) in an ozone‐controlled environment, and data extracted, processed, and normalized using Agilent Feature Extraction (FE) software (v10.5). Raw and processed data files have been deposited in GEO at accessions GSE49887 and GSE66434.

Cell growth assay {#path4633-sec-0014}
-----------------

Cells were infected with lentivirus containing pLDpuro‐GFP, −SMARCA4 or ‐SMARCA2. One day later, cells were selected in 2 µg/ml puromycin for 3 days. The remaining cells were then harvested, counted, and reseeded at a density of 4000 cells per well in 96‐well plates. Cell growth was monitored using the IncuCyte ZOOM^®^ live cell imaging monitor (Essen BioScience, Ann Arbor, MI, USA). The percentage of confluence in each well was calculated and plotted over a 7‐day period to determine the effect of SMARCA4 or SMARCA2 re‐expression on cell growth.

Results {#path4633-sec-0015}
=======

SMARCA4 expression in gynaecological and non‐gynaecological tumours {#path4633-sec-0016}
-------------------------------------------------------------------

We previously studied SMARCA4 protein status in a small series of 485 primary ovarian tumours where besides SCCOHT, only two tumours (0.4%), both clear cell carcinomas, were negative for SMARCA4 [2](#path4633-bib-0002){ref-type="ref"}. In order to perform a definitive analysis of the sensitivity and specificity of SMARCA4 loss for SCCOHT and thus, its potential as a diagnostic immunohistochemical marker, we expanded SMARCA4 IHC analysis to additional cases of SCCOHT and a large series of 3048 primary ovarian and uterine tumours and non‐gynaecological mimics of SCCOHT (Table [1](#path4633-tbl-0001){ref-type="table-wrap"}).

###### 

SMARCA4 immunohistochemical analysis in ovarian, uterine, and selected non‐gynaecological tumours

  Tumour type                                            *n*      SMARCA4‐negative (%)
  --------------------------------------------------- ---------- ----------------------
  *SCCOHT*                                                       
  Primary tumours                                         46           42 (91%) 
  Patient‐derived xenografts                              2             2 (100%)
  Cell lines                                              2             2 (100%)
  **Subtotal**                                          **50**        **46 (92%)**
  *Ovarian epithelial tumours*                                   
  High‐grade serous carcinoma                            1198            0 (0%)
  Clear cell carcinoma                                   360            15 (4%) 
  Endometrioid adenocarcinoma                            258             0 (0%)
  Endometrioid adenocarcinoma, mixed                      9              0 (0%)
  Endometrioid borderline tumour                          1              0 (0%)
  Low‐grade serous carcinoma                              53             0 (0%)
  Serous borderline tumour                                23             0 (0%)
  Mucinous carcinoma                                      98             0 (0%)
  Mucinous borderline tumour                              6              0 (0%)
  Mixed mucinous tumour                                   5              0 (0%)
  Anaplastic carcinoma in mucinous carcinoma              1              0 (0%)
  Mixed carcinoma                                         1              0 (0%)
  Undifferentiated carcinoma                              18             0 (0%)
  Carcinosarcoma                                          27             0 (0%)
  Benign Brenner tumour                                   3              0 (0%)
  Borderline Brenner tumour                               1              0 (0%)
  Malignant Brenner tumour                                2              0 (0%)
  Small cell carcinoma, pulmonary type                    3              0 (0%)
  Ovarian carcinoma, not otherwise specified              5              0 (0%)
  **Subtotal**                                         **2072**       **15 (1%) **
  *Ovarian/adnexal sex cord‐stromal tumours*                     
  Adult granulosa cell tumour                            113             0 (0%)
  Juvenile granulosa cell tumour                          29             0 (0%)
  Fibroma/fibrosarcoma                                    8              0 (0%)
  Thecoma                                                 7              0 (0%)
  Sertoli--Leydig cell tumour                             41             0 (0%)
  Leydig cell tumour                                      2              0 (0%)
  Sclerosing stromal tumour                               6              0 (0%)
  Sex cord tumour with annular tubules                    2              0 (0%)
  Steroid cell tumour                                     1              0 (0%)
  Sex cord tumour, not otherwise specified                4              0 (0%)
  Female adnexal tumour of Wolffian origin                4              0 (0%)
  Gynandroblastoma                                        3              0 (0%)
  Endometrioid stromal sarcoma                            1              0 (0%)
  **Subtotal**                                         **221**         **0 (0%)**
  *Ovarian germ cell tumours*                                    
  Dysgerminoma                                            5              0 (0%)
  Yolk sac tumour                                         6              0 (0%)
  Dysgerminoma and yolk sac tumour                        1              0 (0%)
  Mature teratoma                                         3              0 (0%)
  Immature teratoma                                       6              0 (0%)
  Carcinoid tumour                                        4              0 (0%)
  Strumal carcinoid in a mucinous cystadenoma             2              0 (0%)
  Sebaceous carcinoma in a dermoid cyst                   1              0 (0%)
  Squamous cell carcinoma                                 3              0 (0%)
  **Subtotal**                                          **31**         **0 (0%)**
  *Uterine epithelial tumours*                                   
  Endometrioid adenocarcinoma                            336             1 (0%)
  Clear cell carcinoma                                    28             0 (0%)
  High‐grade serous carcinoma                             94             0 (0%)
  Mucinous carcinoma                                      3              0 (0%)
  Mixed carcinoma                                         11             0 (0%)
  Large cell carcinoma                                    1              0 (0%)
  Small cell carcinoma                                    3              0 (0%)
  Undifferentiated carcinoma                              3              0 (0%)
  Dedifferentiated carcinoma                              2              1 (50%)
  Carcinosarcoma                                          65             0 (0%)
  **Subtotal**                                         **546**         **2 (0%)**
  *Uterine mesenchymal tumours*                                  
  Leiomyoma                                               49             0 (0%)
  Leiomyosarcoma                                          21             0 (0%)
  Endometrial stromal sarcoma                             52             4 (8%)
  Undifferentiated endometrial sarcoma                    1              0 (0%)
  Rhabdomyosarcoma                                        2              0 (0%)
  Adenosarcoma                                            7              0 (0%)
  Uterine tumour resembling ovarian sex cord tumour       2              0 (0%)
  **Subtotal**                                         **134**         **4 (3%)**
  *Non‐gynaecological tumours*                                   
  Alveolar rhabdomyosarcoma                               10             0 (0%)
  Embryonal rhabdomyosarcoma                              10             0 (0%)
  Desmoplastic small round cell tumour                    2              0 (0%)
  Ewing\'s sarcoma                                        9              0 (0%)
  Synovial sarcoma, monophasic                            3              0 (0%)
  Synovial sarcoma, biphasic                              2              0 (0%)
  Melanoma                                                7              0 (0%)
  Follicular lymphoma                                     1              0 (0%)
  **Subtotal**                                          **44**         **0 (0%)**
  **Total**                                            **3048**       **21 (1%) **

Examination of SMARCA4 expression in 50 SCCOHT‐derived samples (20 reported previously [2](#path4633-bib-0002){ref-type="ref"}, [15](#path4633-bib-0015){ref-type="ref"} and 30 new cases reported here) revealed SMARCA4 loss in 42/46 (91%) primary tumours, 2/2 patient‐derived mouse xenografts, and 2/2 SCCOHT‐derived cell lines (Table [1](#path4633-tbl-0001){ref-type="table-wrap"}). Of the four tumours that retained SMARCA4 expression, three lacked SMARCB1 (also called BAF47 or INI1), a different core member of the SWI/SNF complex. One of the three SMARCB1‐negative tumours showed biallelic inactivation of *SMARCB1*. In the remaining SMARCA4‐positive case, exome sequencing revealed no mutations in SWI/SNF genes.

We examined SMARC4 expression in 3048 primary ovarian and uterine tumours and non‐gynaecological mimics of SCCOHT. Among 2324 primary ovarian epithelial, sex cord‐stromal, and germ cell tumours (including the previously reported 485 tumours [2](#path4633-bib-0002){ref-type="ref"}), SMARCA4 loss was only observed in clear cell carcinoma (15/360, 4%) (Table [1](#path4633-tbl-0001){ref-type="table-wrap"}), a tumour that is not in the histological differential diagnosis of SCCOHT. All ovarian tumours in the histological differential diagnosis of SCCOHT (including small cell carcinoma of pulmonary type, adult and juvenile granulosa cell tumours, Sertoli--Leydig cell tumours, endometrial stromal sarcoma, and dysgerminoma) retained SMARCA4 expression.

Among 680 primary uterine tumours, SMARCA4 loss was observed in endometrioid carcinoma (2/338, 1%) and endometrial stromal sarcoma (ESS, 4/52, 4%; Table [1](#path4633-tbl-0001){ref-type="table-wrap"}). Both endometrioid carcinomas were FIGO grade 3; one was a dedifferentiated carcinoma [16](#path4633-bib-0016){ref-type="ref"}, a tumour composed of low‐grade endometrioid carcinoma (FIGO grade 1 or 2) and undifferentiated carcinoma. Among the ESS cases, two were low‐grade and two were high‐grade. One high‐grade ESS showed rhabdoid features. For the SMARCA4‐negative dedifferentiated carcinoma and the high‐grade ESS cases, only the high‐grade/undifferentiated portions were represented on the TMAs.

We also examined SMARCA4 expression in 44 extra‐ovarian, non‐gynaecological tumours that resemble SCCOHT histologically and can present with intra‐abdominal or ovarian disease mimicking ovarian carcinoma clinically, including alveolar and embryonal rhabdomyosarcoma, desmoplastic small round cell tumour, Ewing\'s sarcoma, synovial sarcoma, follicular lymphoma, and melanoma. All of these tumours retained SMARCA4 expression (Table [1](#path4633-tbl-0001){ref-type="table-wrap"}).

In summary, 46/50 (92%) of all SCCOHT‐derived samples in our series lacked SMARCA4, and 49/50 (98%) lacked a core member of the SWI/SNF complex (either SMARCA4 or SMARCB1). When combined with other published SCCOHT cases [3](#path4633-bib-0003){ref-type="ref"}, [4](#path4633-bib-0004){ref-type="ref"}, [5](#path4633-bib-0005){ref-type="ref"}, SMARCA4 loss has now been observed in 83/91 cases (91% sensitivity). Among primary ovarian tumours and non‐gynaecological tumours that can mimic SCCOHT, we observed SMARCA4 loss in only 15/2368 tumours (15/2324 ovarian and 0/44 non‐gynaecological) for a specificity of 99% among the tumours examined, and the only ovarian tumour that lacked SMARCA4 in our study (clear cell carcinoma) is not in the differential diagnosis of SCCOHT. These data demonstrate that the lack of SMARCA4 in ovarian tumours is a highly sensitive and almost completely specific IHC marker of SCCOHT.

Absence of SMARCA2 protein in SCCOHT tumours {#path4633-sec-0017}
--------------------------------------------

In order to determine SMARCA2 status in SCCOHT and the potential for its development as a therapeutic target, we examined its expression in 45 cases. All 45 tumours (43 lacking SMARCA4 and 2 lacking SMARCB1) were negative for SMARCA2. However, rare tumour cells (usually \< 1% but up to 10% focally) still expressed SMARCA2. In areas containing only small cells, SMARCA2 staining was exclusively nuclear (Figure [1](#path4633-fig-0001){ref-type="fig"}A, arrows). In tumours with a large cell component, the protein was exclusively localized to the cytoplasm of large cells (Figure [1](#path4633-fig-0001){ref-type="fig"}B, bottom panels, arrowheads), with no cytoplasmic expression in the small cell component (Figure [1](#path4633-fig-0001){ref-type="fig"}B, upper panels).

![Immunohistochemical analysis of core SWI/SNF proteins in SCCOHT. (A) Dual loss of SMARCA4/BRG1 and SMARCA2/BRM in SCCOHT. Endothelium and lymphocytes are internal positive controls for both proteins. Arrows denote rare tumour cells expressing SMARCA2. SMARCB1/INI1 protein expression serves as a positive control for tumour cell immunoreactivity. (B) SMARCA2/BRM expression and subcellular localization in regions of small cell versus large cell morphology. When present, SMARCA2 only showed nuclear localization in the small cells (arrows, A). In contrast, scattered tumour cells with large cell morphology also expressed SMARCA2 in the cytoplasm (arrowheads, B). (C) SMARCA4/BRG1 and SMARCA2/BRM expression in normal ovary from premenopausal women. SMARCA4 was expressed strongly in oocytes and granulosa cells but was either weak or absent in stromal cells. In contrast, SMARCA2 showed diffuse and strong expression in oocytes, granulosa cells, and stromal cells. In addition, both proteins showed uniform expression in ovarian surface epithelium (data not shown). H&E and SMARCA4 immunohistochemistry images are reproduced from our previous publication, Ramos et al [2](#path4633-bib-0002){ref-type="ref"} (Supplementary Figure [4](#path4633-fig-0004){ref-type="fig"}, panels A--D).](PATH-238-389-g001){#path4633-fig-0001}

We did not identify mutations in the *SMARCA2* gene in SCCOHT, implicating silencing during tumourigenesis or in the cell of origin as the underlying mechanism explaining the absence of SMARCA2 protein. We therefore performed IHC for SMARCA2 in ovaries of premenopausal women and found uniform and strong expression in all ovarian cell types, including surface epithelial cells, stromal cells, granulosa cells, theca cells, and oocytes (Figure [1](#path4633-fig-0001){ref-type="fig"}C). This result suggests that SCCOHT loses SMARCA2 expression during tumourigenesis or, alternatively, SCCOHT arises from a rare SMARCA2‐negative cell type in the ovary.

To determine whether dual loss of both SMARCA4 and SMARCA2 was specific for SCCOHT, we examined SMARCA2 expression by IHC in ovarian clear cell carcinoma, the only other tumour lacking SMARCA4 expression (Table [1](#path4633-tbl-0001){ref-type="table-wrap"}). Tumours were deficient either for SMARCA4 or for SMARCA2, but not both (Figure [2](#path4633-fig-0002){ref-type="fig"}), indicating that dual deficiency of the two SWI/SNF ATPases is specific for SCCOHT. In uterine tumours, combined SMARCA4 and SMARCA2 deficiency was only observed in dedifferentiated carcinoma (*n* = 1) and high‐grade ESS (*n* = 2) (Figure [3](#path4633-fig-0003){ref-type="fig"}).

![Immunohistochemical analysis of SMARCA4/BRG1 and SMARCA2/BRM in ovarian clear cell carcinoma. Tumours were negative for either SMARCA4 (middle panels) or SMARCA2 (bottom panels) or showed intact expression of both proteins (upper panels). No dual deficient tumours were identified. Similar to SCCOHT, rare scattered SMARCA2‐positive cells (arrows) were identified in some SMARCA2‐negative tumours.](PATH-238-389-g002){#path4633-fig-0002}

![Immunohistochemical analysis of SMARCA4/BRG1 and SMARCA2/BRM in endometrial stromal sarcoma (ESS) and dedifferentiated carcinoma (DDC) of the uterus. Three uterine tumour types showed SMARCA4/BRG1 deficiency: low‐grade ESS (LGESS, n = 2, upper panels), high‐grade ESS (HGESS, n = 2, middle panels), and DDC (n = 1, lower panels). Both cases of SMARCA4‐negative LGESS maintained expression of SMARCA2. In contrast, both HGESS and the DDC that lacked SMARCA4 were also deficient in SMARCA2.](PATH-238-389-g003){#path4633-fig-0003}

Epigenetic silencing of SMARCA2 in SCCOHT cells {#path4633-sec-0018}
-----------------------------------------------

The lack of mutations or deletions involving *SMARCA2* in SCCOHT and the expression of SMARCA2 protein in rare tumour cells suggest that the absence of SMARCA2 protein in most tumour cells arises from epigenetic silencing or mRNA degradation, as reported in other SMARCA2‐deficient cell lines [17](#path4633-bib-0017){ref-type="ref"}, [18](#path4633-bib-0018){ref-type="ref"}, [19](#path4633-bib-0019){ref-type="ref"}, [20](#path4633-bib-0020){ref-type="ref"}, [21](#path4633-bib-0021){ref-type="ref"}. Compared with normal premenopausal ovary, *SMARCA2* mRNA levels were decreased in seven SCCOHT tumour samples (four primary tumours and two mouse xenografts generated directly from patient tumours, and one SCCOHT cell line), an effect that was specific for *SMARCA2* and not observed with genes encoding most other SWI/SNF family members (Figure [4](#path4633-fig-0004){ref-type="fig"}A). Similar to the tumour samples, no *SMARCA2* mRNA (Figure [4](#path4633-fig-0004){ref-type="fig"}B) or protein (Figure [4](#path4633-fig-0004){ref-type="fig"}C, S1) was detected in two SCCOHT cell lines, BIN67 and SCCOHT1, and no underlying mutation was identified. *SMARCA2* mRNA levels were significantly lower in BIN67 and SCCOHT1 cells than in NOY1 (a yolk sac tumour cell line), SVOG3e (an immortalized primary granulosa cell line) or KGN cells (an adult granulosa cell tumour cell line) (Figure [4](#path4633-fig-0004){ref-type="fig"}B), suggesting epigenetically silencing of the *SMARCA2* gene or degradation of *SMARCA2* mRNA as the mechanism underlying the lack of SMARCA2 protein in SCCOHT cells.

![SMARCA2 silencing in SCCOHT tumours and cell lines and reactivation by the histone deacetylase inhibitor trichostatin A. (A) Heat map depicting the expression of genes encoding SWI/SNF family members in SCCOHT tumours (SCCO‐002, ‐012, ‐014, and ‐015), patient‐derived mouse xenografts (PDX‐040 and −065), and SCCOHT cell lines (BIN67 and SCCOHT1). SMARCA2 mRNA is strongly down‐regulated in contrast to almost all other SWI/SNF genes. Premenopausal ovaries were used as a reference. (B) Real‐time PCR of steady‐state SMARCA4 and SMARCA2 mRNA levels in SCCOHT cell lines (BIN67 and SCCOHT1) compared with other ovarian cell lines. SVOG3e: immortalized granulosa cells; KGN: adult granulosa cell line; NOY1: yolk sac tumour cell line. Levels of mRNA were normalized to GAPDH. (C) Western blotting for SMARCA4 and SMARCA2 in SCCOHT cell lines. Vinculin served as a loading control. Both SCCOHT cell lines expressed SMARCB1/INI1 (data not shown), similar to primary tumours (Figure [1](#path4633-fig-0001){ref-type="fig"}A). (D) Specific up‐regulation of SMARCA2/BRM protein by the histone deacetylase inhibitor trichostatin A (TSA). BIN67 cells were treated for 72 h with TSA, GSK343, trametinib or 5‐azacytidine, and SMARCA2 expression was analysed by western blotting. Ctrl denotes vehicle treatment. SMARCA2 (lane 2) denotes cells transduced with lentivirus expressing SMARCA2. KGN: adult granulosa cell tumour cells. Ponceau S staining served as a loading control. (E) Real‐time PCR of SMARCA4 and SMARCA2 mRNA levels in BIN67 cells after 72 h of treatment with 0.6 µ[m]{.smallcaps} TSA. Although absolute baseline SMARCA2 mRNA levels are significantly lower than SMARCA4 (Figure [4](#path4633-fig-0004){ref-type="fig"}B), both are arbitrarily set to 1 in this experiment. SMARCA2 mRNA levels are strongly up‐regulated by TSA compared with SMARCA4. (F) SMARCA2 protein up‐regulation is TSA‐dose‐dependent in SCCOHT cell lines. BIN67 and SCCOHT1 cells were treated with increasing doses of TSA for 72 h, and SMARCA2 expression was analysed by western blotting. Ctrl denotes vehicle treatment. SMARCA2 (lane 2 for each cell line) denotes cells transduced with lentivirus expressing SMARCA2. ES‐2: ovarian endometrioid adenocarcinoma cells. Ponceau S staining served as a loading control.](PATH-238-389-g004){#path4633-fig-0004}

To determine whether we could reactivate SMARCA2 expression in SCCOHT cell lines, we treated BIN67 cells with inhibitors that target epigenetic regulators including the HDAC inhibitor trichostatin A (TSA), the DNA methyltransferase inhibitor 5‐azacytidine (5‐AZA), and the EZH2 histone methyltransferase inhibitor GSK343. Of these reagents, only the HDAC inhibitor TSA induced the expression of SMARCA2 protein (Figure [4](#path4633-fig-0004){ref-type="fig"}D), correlating with increased mRNA levels in BIN67 cells (Figure [4](#path4633-fig-0004){ref-type="fig"}E). Furthermore, TSA stimulated the expression of SMARCA2 protein in a dose‐dependent manner in BIN67 and SCCOHT1 cells (Figure [4](#path4633-fig-0004){ref-type="fig"} F). These data implicate HDAC‐mediated epigenetic silencing of the *SMARCA2* gene in SCCOHT or, alternatively, an indirect inhibitory effect on *SMARCA2* mRNA degradation.

Re‐expression of SMARCA4 or SMARCA2 inhibits cell growth {#path4633-sec-0019}
--------------------------------------------------------

To assess whether the absence of SMARCA4 and SMARCA2 is crucial for tumour cell growth, we infected BIN67 cells with lentiviruses driving expression of SMARCA4 or SMARCA2. Overexpression of either protein robustly suppressed the growth of BIN67 cells (Figure [5](#path4633-fig-0005){ref-type="fig"}A). However, SMARCA4 expression did not significantly inhibit the growth of cells lacking only SMARCA4 (JHOC5 cells, ovarian clear cell carcinoma cell line [22](#path4633-bib-0022){ref-type="ref"}) or with normal SMARCA4 and SMARCA2 expression (ES‐2 ovarian endometrioid adenocarcinoma cell line [22](#path4633-bib-0022){ref-type="ref"}) (data not shown). Previous studies have shown that the ability of SMARCA4 to induce cell cycle arrest in SMARCA4/SMARCA2‐deficient cell lines is dependent on a functional retinoblastoma growth control pathway [17](#path4633-bib-0017){ref-type="ref"}, [19](#path4633-bib-0019){ref-type="ref"}, [23](#path4633-bib-0023){ref-type="ref"}, [24](#path4633-bib-0024){ref-type="ref"}, [25](#path4633-bib-0025){ref-type="ref"}, [26](#path4633-bib-0026){ref-type="ref"}. Therefore, the rapid growth arrest that SMARCA4 or SMARCA2 expression induced in SCCOHT cells is consistent with the absence of detectable *RB1* gene mutations in all tumour samples and the presence of intact, full length RB1 protein (both hypo‐ and hyper‐phosphorylated forms) in the BIN67 cells (data not shown).

![Re‐expression of SMARCA4 or SMARCA2 suppresses SCCOHT cell growth. (A) BIN67 cells were transduced with lentiviruses expressing GFP, SMARCA4 or SMARCA2 and seeded at a density of 4000 cells per well in 96‐well plates for monitoring cell growth using an IncuCyte ZOOM® live cell monitor. The percentage of confluence in each well was calculated and plotted to determine the effect of SMARCA4 or SMARCA2 re‐expression on cell growth. (B) Re‐expression of SMARCA4 or SMARCA2 was confirmed by western blotting. Ponceau S staining served as a loading control.](PATH-238-389-g005){#path4633-fig-0005}

Discussion {#path4633-sec-0020}
==========

SMARCA4 in ovarian and endometrial tumours {#path4633-sec-0021}
------------------------------------------

Almost all SCCOHTs contain inactivating somatic and germline mutations in *SMARCA4* that result in loss of the SMARCA4 (BRG1) protein. We investigated SMARCA4 expression by IHC in a large collection of gynaecological and non‐gynaecological tumours to determine the specificity of SMARCA4 loss for SCCOHT. All tumours in the differential diagnosis that we examined retained SMARCA4 expression. The only primary ovarian tumour other than SCCOHT that showed loss of SMARCA4 -- clear cell carcinoma -- does not enter the histological differential diagnosis of SCCOHT. Therefore, the absence of SMARCA4 is highly sensitive and essentially completely specific for SCCOHT.

Though we only studied small numbers of germ cell tumours in the differential diagnosis of SCCOHT, our results are consistent with those of Witkowski *et al*, who found no *SMARCA4* mutations in 106 germ cell tumours, including 25 dysgerminomas and seminomas [27](#path4633-bib-0027){ref-type="ref"}. A few ovarian tumours in the differential diagnosis of SCCOHT were not studied, including metastatic small cell lung carcinoma and oxyphilic tumours that can resemble the large cell variant of SCCOHT. In addition, we did not examine small cell carcinoma of the endometrium or cervix; notably, the latter has been reported to be deficient in SMARCA4 [28](#path4633-bib-0028){ref-type="ref"}. Though SCCOHT and cervical small cell carcinoma have distinct clinical presentations, other IHC markers (eg WT1 and TTF1) [29](#path4633-bib-0029){ref-type="ref"} or molecular studies (HPV18 in the cervical tumours) [28](#path4633-bib-0028){ref-type="ref"}, [30](#path4633-bib-0030){ref-type="ref"} can also be used to distinguish between these entities.

The near universal expression of SMARCA4 as determined by IHC contrasts with the presence of *SMARCA4* point mutations or deletions reported in several tumours in our study such as high‐grade serous carcinomas [9](#path4633-bib-0009){ref-type="ref"}, [10](#path4633-bib-0010){ref-type="ref"}, [31](#path4633-bib-0031){ref-type="ref"}, [32](#path4633-bib-0032){ref-type="ref"}, [33](#path4633-bib-0033){ref-type="ref"}. Different mutation types in these tumours compared with those in SCCOHT likely underlie this apparent discrepancy. Of almost 100 *SMARCA4* mutations reported in SCCOHT, all but three are destructive to the protein (truncating, frameshift, spice site or deletions) [15](#path4633-bib-0015){ref-type="ref"} with common bi‐allelic inactivation due to mutation or loss of heterozygosity of the second allele [3](#path4633-bib-0003){ref-type="ref"}, [5](#path4633-bib-0005){ref-type="ref"}. In contrast, approximately 80% of *SMARCA4* mutations found in more than 500 other tumour samples are missense and do not typically involve inactivation of the second allele [9](#path4633-bib-0009){ref-type="ref"}, [10](#path4633-bib-0010){ref-type="ref"}, [31](#path4633-bib-0031){ref-type="ref"}, [32](#path4633-bib-0032){ref-type="ref"}. Therefore, several tumours in our study may harbour missense mutations in *SMARCA4* that, by their nature, were not suggested by IHC. Interestingly, although ovarian high‐grade serous carcinomas reportedly show mutually exclusive homozygous deletions in *SMARCA4* and *SMARCA2* [31](#path4633-bib-0031){ref-type="ref"}, [32](#path4633-bib-0032){ref-type="ref"}, we did not observe SMARCA4 protein loss in any of our samples. This apparent discrepancy might be explained by the extreme intratumoural heterogeneity [34](#path4633-bib-0034){ref-type="ref"} that characterizes this tumour. Accordingly, it seems unlikely that random selection of two different areas of a tumour for inclusion in a TMA would result in all tumour cells in both regions having homozygous deletions in *SMARCA4*.

Silencing of SMARCA2 in SCCOHT {#path4633-sec-0022}
------------------------------

Several groups recently demonstrated that SMARCA4‐deficient lung cancer cells depend on SMARCA2, the other mutually exclusive ATPase in SWI/SNF complexes, for proliferation and survival [11](#path4633-bib-0011){ref-type="ref"}, [12](#path4633-bib-0012){ref-type="ref"}, [35](#path4633-bib-0035){ref-type="ref"}, suggesting that SMARCA2 could be a therapeutic target in *SMARCA4*‐mutant tumours. However, this requirement is not absolute, as some cell lines [11](#path4633-bib-0011){ref-type="ref"}, [12](#path4633-bib-0012){ref-type="ref"}, [13](#path4633-bib-0013){ref-type="ref"}, [17](#path4633-bib-0017){ref-type="ref"}, [19](#path4633-bib-0019){ref-type="ref"}, [23](#path4633-bib-0023){ref-type="ref"}, [24](#path4633-bib-0024){ref-type="ref"}, [25](#path4633-bib-0025){ref-type="ref"}, [26](#path4633-bib-0026){ref-type="ref"} and lung cancers [36](#path4633-bib-0036){ref-type="ref"}, [37](#path4633-bib-0037){ref-type="ref"} lack both ATPases. Similar to the lung cancers with poor prognosis that lack both SMARCA4 and SMARCA2 [37](#path4633-bib-0037){ref-type="ref"}, all SMARCA4‐deficient SCCOHTs were also deficient for SMARCA2. In addition, as previously reported for other *SMARCA4*‐mutant tumours with loss of SMARCA2 expression [18](#path4633-bib-0018){ref-type="ref"}, [19](#path4633-bib-0019){ref-type="ref"}, [20](#path4633-bib-0020){ref-type="ref"}, [21](#path4633-bib-0021){ref-type="ref"}, we could restore SMARCA2 expression by treatment of SCCOHT cell lines with the HDAC inhibitor TSA. We have found that HDAC inhibitors are potent inducers of SMARCA2 and growth arrest in SCCOHT cell lines (data not shown). Based on the pleotropic effects of HDAC inhibitors on global gene expression, we think that it is unlikely that SMARCA2 up‐regulation is the sole mechanism by which these agents cause growth arrest. We are currently performing shRNA studies against *SMARCA2* and with specific HDACs (guided by the known HDAC specificity of the particular HDAC inhibitors) to determine the role that SMARCA2 plays in HDAC inhibitor‐induced growth arrest and which HDACs mediate the growth inhibitory effect. Therefore, our results strongly support silencing, either transcriptional or post‐transcriptional, as the mechanism underlying the absence of *SMARCA2* gene expression in these tumours and implicate HDAC inhibitors as potential treatment options.

Among ovarian tumours, dual loss of SMARCA4 and SMARCA2 was only observed in SCCOHT. Ovarian clear cell carcinomas lacked SMARCA4 or SMARCA2 but not both. Similarly, Huang *et al* recently reported no loss of SMARCA4 in 68 ovarian clear cell carcinomas, with only one tumour showing SMARCA2 loss [38](#path4633-bib-0038){ref-type="ref"}, and although almost all SCCOHT tumour cells lacked SMARCA2, rare SMARCA2‐positive tumour cells were identified and the subcellular localization correlated with cell morphology -- exclusively nuclear in small cells and either nuclear or cytoplasmic in large cells. Cytoplasmic SMARCA2 in large cells of SCCOHT is reminiscent of the cytoplasmic SMARCB1 staining observed in some cases of epithelioid sarcoma [39](#path4633-bib-0039){ref-type="ref"}. These findings suggest that in addition to mutation and gene silencing, SWI/SNF defects may also be due to protein mislocalization.

Potential cells of origin {#path4633-sec-0023}
-------------------------

SCCOHT may arise from resident ovarian cells or from a cell type within an immature teratoma [4](#path4633-bib-0004){ref-type="ref"}. The conspicuous lack of *SMARCA2* mutations in three papers that identified the *SMARCA4* mutation in SCCOHT by next‐generation sequencing [2](#path4633-bib-0002){ref-type="ref"}, [3](#path4633-bib-0003){ref-type="ref"}, [5](#path4633-bib-0005){ref-type="ref"}, together with the up‐regulation of *SMARCA2* mRNA and translated protein by the histone deacetylase inhibitor trichostatin A, indicates that the lack of SMARCA2 protein expression is due to either epigenetic or post‐transcriptional silencing. The lack of SMARCA2 expression in tumours may reflect either its original absence in the cell of origin or silencing as a pathogenic event during tumourigenesis. Lentivirus‐mediated restoration of wild‐type SMARCA4 does not result in re‐expression of endogenous SMARCA2 protein, whereas HDAC inhibitors do result in SMARCA2 protein expression (data not shown). This differential SMARCA2 protein up‐regulation is not likely due to differences in the effects of SMARCA4 expression or HDAC inhibitor treatment on the cell cycle since both manipulations result in growth arrest. We speculate that the inability of exogenous SMARCA4 to restore endogenous SMARCA2 expression reflects the origin of SCCOHT from a rare SMARCA2‐negative cell.

Molecular pathogenesis {#path4633-sec-0024}
----------------------

The function of the SWI/SNF complex in transcriptional regulation, the absence of other recurrent mutations, and the diploid cytogenetic profile of SCCOHT indicate that the principal mechanism of oncogenesis is epigenetic dysregulation. The pathological features -- poorly differentiated and highly proliferative -- suggest that the principal defect is the failure to activate genes that promote or maintain terminal differentiation.

The role of the SWI/SNF complex in regulating differentiation as a potential mechanism of SCCOHT pathogenesis is also suggested by the uterine tumours with combined loss of both SMARCA4 and SMARCA2 -- dedifferentiated carcinoma and high‐grade ESS. These tumours are conceptually similar in that they both have low‐ and high‐grade areas separated by an abrupt transition indicating a dedifferentiation event and, like SCCOHT, they both can show small cell or rhabdoid features in the high‐grade areas [16](#path4633-bib-0016){ref-type="ref"}, [40](#path4633-bib-0040){ref-type="ref"}.

We propose that dual deficiency in core members of the SWI/SNF complex (eg SMARCA4 and SMARCA2 or SMARCB1 and SMARCA2) induces dedifferentiation from a normal cell or a low‐grade tumour into an aggressive high‐grade tumour with small cell and/or rhabdoid features. Similar to our findings in SCCOHT, malignant rhabdoid tumours also show dual deficiency for core SWI/SNF members: SMARCB1 by mutation and SMARCA2 by non‐mutational silencing [41](#path4633-bib-0041){ref-type="ref"}, [42](#path4633-bib-0042){ref-type="ref"}, [43](#path4633-bib-0043){ref-type="ref"}. The shared clinicopathological features of SCCOHT and rhabdoid tumours of the brain and kidney -- lethal behaviour, diploid cytogenetics, small cell/rhabdoid histology, and dual loss of core SWI/SNF components (one by mutation, one by silencing) -- support the proposal that SCCOHT is a malignant rhabdoid tumour of the ovary, as proposed by Foulkes *et al* [44](#path4633-bib-0044){ref-type="ref"}. More importantly, the shared genetics of rhabdoid tumours will hopefully predict their response to drugs that target epigenetic modifications. Our preliminary studies on HDAC inhibitors support this notion.
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SUPPORTING INFORMATION ON THE INTERNETThe following supporting information may be found in the online version of this article:**Figure S1.** Specificity of SMARCA4 and SMARCA2 antibodies by western blot.
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